Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01812148

Enrollment

Registered

2013-03-18

Start date

2012-01-31

Completion date

2013-03-31

Last updated

2013-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal Mesotheliomas

Keywords

Peritoneal Mesotheliomas, hyperthermic intra-peritoneal chemotherapy (HIPEC), Oxaliplatin, Cytoreductive surgery, Oxaliplatin HIPEC

Brief summary

Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.

Detailed description

Observation of primary outcome: * Overall Survival * Disease-free survival Influencing factors that will be observe: * Sex * Blood loss * Time of surgery * Number of resection and anastomosis * Peritoneal Index (PI score) * Cytoreductibility (CCR score)

Interventions

PROCEDURECytoreductive surgery and HIPEC

Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent

Study design

Observational model

CASE_CROSSOVER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Peritoneal mesothelioma

Exclusion criteria

* Non resectable disease

Design outcomes

Primary

Measure	Time frame
Overall survival	5 years

Secondary

Measure	Time frame
Disease-Free survival	5 years

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026